QIAGEN and Pfizer Partner to Develop Companion Diagnostic for Novel Compound in Global Clinical Trials for Lung Cancer
GERMANTOWN, Maryland and HILDEN, Germany, August 16, 2011 /PRNewswire/ --
- Diagnostic-therapeutic combination aims to improve standard of care for patients with non-small cell lung cancer (NSCLC)
- Molecular test for KRAS gene mutations holds potential to help determine whether there is a subset of patients who are more likely to benefit from Pfizer's investigational anticancer compound
- Collaboration in lung cancer follows QIAGEN's two FDA submissions of KRAS mutation-based companion diagnostics in metastatic colorectal cancer treatment
- Partnership builds on QIAGEN's leadership in Personalized Healthcare, with more than 15 co-developments and 20 companion diagnostics
QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced it has entered into a partnership with Pfizer Inc. (NYSE: PFE) for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer (NSCLC). Financial terms of the agreement were not disclosed.
Pfizer's investigational compound, dacomitinib (PF-00299804), is an oral inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. The HER (human epidermal growth factor receptor) signaling pathway plays a role in the complex process of cell growth and metastasis, making it a target for anti-cancer drugs.
QIAGEN's proposed companion diagnostic will be based on its proprietary KRAS assay technology, which reliably detects mutations of the KRAS gene that are frequently found in human cancers. Because EGFR inhibitors are generally effective in patients without these KRAS mutations